The Longevity Compound Promoted on Half a Mechanism

If you've been reading these in order, you came for the arteries: the stent at 44, the tests that called me healthy, the plaque a calcium score can't see. This one deviates from that storyline, and the pivot is on purpose. Getting a stent at 44 despite doing all the right things made me stop and start running a systematic process over every claim, podcaster opinion, and longevity-guru recommendation I'd folded into my life. The first one I put to the test was the claim that LDL doesn't matter if you're metabolically healthy. It didn't stop there. I'd been spending thousands of dollars a year on supplements, routines, and biohacking gear, and I realized everything I thought I knew had to be checked.

I'll keep writing about cardiovascular disease, because that was the event that forced me to reevaluate my whole outlook on health, wellness, and longevity. But my own story doesn't end with a villain. There's no single thing to point at and blame for how fast my disease moved. I'm still exploring it, and I'll bring you along, but I've started to doubt a true smoking gun exists. It was probably a combination of factors, high LDL among them, plus other risks that still slip past the modern diagnostic stack.

The reason I built Calibrated was never that I'm angry about a stent at a stupidly young age. It's this. For years I was the guy spending thousands of dollars a year on longevity and health: the supplements, the compounds, the protocols, chasing every edge the marketing promised. More recently I spent years doing the harder version, running those same interventions through rigorous, academic-quality computational analysis and evidence pipelines. Every study I can find, the conflicts behind them, whether the stuff even absorbs, how the evidence was actually built. Not the mechanism cartoon on the sales page. Stories start with mechanism. They shouldn't end there.

Here's the part people expect me to say, and I'll get ahead of it before I'm written off as a reflexive skeptic: I didn't stop spending. I still put real money into my health every year. I just got a lot smarter about where it goes.

This is the first full examination of a compound making the rounds online for health and longevity. I wanted it to be real.

A newsletter I follow spent last week promoting a compound called 5-Amino-1MQ: better muscle, less fat, sharper focus, maybe even a healthier heart. It rides the same NAD⁺ wave you've heard about with NMN and NR, the supplements sold to top up the cell's energy currency. But it takes a different route. Instead of adding raw material, it's proposed to block an enzyme, NNMT, that drains the supply. And the biology underneath it isn't stupid. NNMT is a real enzyme. The mouse data aren't imaginary. If a molecule could do half of what's on that list, I'd want it in my own life.

Before I pivoted to graduate school, molecular biology, computational biology, the bench, and now clinical medicine, I spent fifteen years inside the supplement industry. Long enough to raise an eyebrow as high as Dwayne "The Rock" Johnson when a science post ends with the author's personal dose and a discount code. So I didn't take the pitch. I read the papers. Not just the few the article pointed at. All of them, run through the evidence pipeline.

Here's what stopped me, and it wasn't that the evidence is animal-only. The author concedes that part himself.

The Bottom Line To get from these studies to justifying real money on that capsule, you're asked to cross four bridges. Not one of them has been built.

1. From mice to humans. Eleven studies of this compound exist. Every one is in cells or rodents. Not a single human has ever been dosed in a trial, even for safety.
2. From a needle to a pill. Every result worth quoting came from injecting rodents. The compound has never been shown to absorb by mouth in people, and they're selling you a tablet.
3. The people who patented it run the studies. Every study behind the muscle and fat claims traces to the one lab whose founder patented the molecule and started the company that sells it. No independent group has reproduced any of it.
4. From a chalkboard arrow to your heart. The "it protects your heart" claim rests on one pathway sketch that has never been measured, while the better-established biology runs the other way and might point toward harm. That one stopped me cold, as a guy with a recent stent.

Cross all four and you've got a longevity protocol. Build none of them and you've got an interesting mouse study with a price tag. I looked hard at this one. I changed nothing.

Vocabulary that matters

• NNMT — an enzyme that uses up two of your cells' resources (a methyl group and a piece of the NAD⁺ supply chain). Block it, the theory goes, and you free those resources back up.
• NAD⁺ — a molecule central to how cells make energy. It falls with age, which is why "raises NAD⁺" is catnip in the longevity world.
• 1-MNA — the product NNMT makes. Remember this one. It matters more than the marketing lets on.
• Research chemical — not a supplement, not a drug. A compound sold "for research use only, not for human consumption," with no FDA approval and no quality standard you can lean on.

Why a stent patient reads this one heart-first

The pitch for compounds like this is always some version of trust the mechanism. The biology makes sense, the animal data look great, conventional medicine is just too slow to catch up. I understand the appeal. I spent fifteen years in the supplement industry selling optimism exactly like it. That's why I can smell it a mile away now.

Here's the thing about "trust the mechanism": if mechanism is your whole case, you have to read all of it and trace out every side of the pathway, not just the flattering half. When I read all of it on 5-Amino-1MQ, three things jumped out that the newsletter never mentioned.

What the marketing skips

It has never been tested in a human. Every result you've seen, the 40% strength gain,² the muscle regeneration,³ the fat loss without dieting,¹ came from mice. Eleven studies of the real compound, and the count of human trials is zero. No efficacy data. No safety data. Nothing. When someone calls a compound "low-risk" with no human safety record, understand what that sentence actually means: nobody has checked. There's a whole graveyard of molecules that never made it into humans for exactly one reason. They turned out to be unsafe in some population. With no human data, there is no way to know whether you're in that population.

The interesting animal results were injected, and they're selling you a pill. Every one of those animal benefits was produced by injection, into the bloodstream or the belly (in the lab we call the latter intraperitoneal).^1,2,3,4 Not one efficacy study used the oral route the capsules are sold in. And that's not an accident. One research team wrote, in plain text, that they injected the compound because it absorbs so poorly by mouth.⁴ Oral absorption is poor in mice and only partial in rats;⁵ in humans it has never been measured at all. So the headline numbers came from a needle and a controlled dose of pure compound. The pill on the website is an unmeasured dose of an unverified powder, betting that whatever survives your gut does what the injection did. That bet has no study behind it.

Follow the money, because this is the part that's genuinely unusual. I've mapped the evidence behind thousands of studies across more than a hundred interventions, and I rarely see one this captured. Every animal study behind the metabolic and muscle claims comes out of a single lab: the lab whose principal investigator went on to found the company that now licenses and sells the compound.^6,7 Four of those papers disclose that company tie in their competing-interests statement. The other two state "no conflict of interest," even though they come from that same lab. I'm not alleging anyone hid anything. I'm telling you what the public record shows: no unaffiliated group has ever reproduced these results, and there is not one null result in the entire library. A spotless record from a single interested source isn't a literature. It's a brochure.

The heart arrow points the other way

Now the fourth bridge, the cardiovascular claim, because this is where I live.

The story being sold is tidy: NNMT drives up homocysteine, homocysteine is bad for arteries, so block NNMT and you protect the heart. Clean arrow on a slide.

First problem: it has never been measured. Not one study has shown 5-Amino-1MQ changes homocysteine in anything, human, animal, or cell. It's a chalkboard mechanism, asserted, not demonstrated. And even the next link is shaky. When large human trials actually lowered homocysteine with B vitamins, across more than 37,000 people, heart attacks and strokes didn't budge.¹³

Second problem, and the bigger one: the arguably better-established evidence runs the other way. Remember 1-MNA, the molecule NNMT makes? In humans, 1-MNA improves the function of the lining of your blood vessels, the nitric-oxide system your arteries run on.⁸ In atherosclerosis-prone animals it reduces arterial plaque and calms platelets, both anti-atherosclerotic and anti-clotting.⁹ It's one of the only pieces of this whole story with any human cardiovascular data at all, and it points toward protection.

Now connect the dots. 5-Amino-1MQ works by shutting down NNMT, the exact enzyme that produces 1-MNA. Lowering 1-MNA isn't a side effect; it is the mechanism. A study of a related NNMT blocker confirmed the drop, about 77%.¹¹ So the thing sold as cardioprotective directly suppresses a molecule shown, in people, to protect blood vessels.⁸ And the enzyme itself looks protective under stress: when researchers blocked NNMT in blood-vessel cells under oxidative pressure, the cells survived worse.¹² Here's a wrinkle I'll come back to in a future post. A meaningful share of people carry genetic variants in that same nitric-oxide pathway and have never been tested for them. If you're one of them, this is a compound that could, in theory, push your cardiovascular health the wrong way. That's still chalkboard mechanism. But it's the exact same kind of reasoning being used to sell the benefits.

I'll be fair to the other side, because honest is the whole job here. That related-compound study ran in already-sick "stiff-heart" mice, and it did show cardiac benefit, but through reducing a different set of byproducts, not the homocysteine route on the slide.¹¹ There's even a real twist that could favor the compound: blocking NNMT also lowers two niacin byproducts, 2PY and 4PY, that are independently tied to heart attacks in large human studies.¹⁰ But notice that this is a completely different mechanism than the one being marketed, and it's still mouse-and-association data, not a human outcome.

The Read: When your entire case is mechanism, you don't get to show me only the half that sells. I'm not telling you this compound harms your heart. Nobody has tested that, in either direction, in a single human. I'm telling you "protects your heart" is a guess, the better-established evidence leans the other way, and for a guy with a stent, "we don't know, and it might cut the wrong way" is a full stop.

What the aging clocks say

Nothing yet. No validated epigenetic-clock data exist for this compound. And there's a trap worth naming: because 5-Amino-1MQ might shift the cell's methylation economy, a "younger" reading on a methylation clock could be a measurement artifact rather than real rejuvenation. If a vendor ever waves a clock result at you, that's the first question to ask. The full hallmark-by-hallmark breakdown lives in the database (below).

What I changed: absolutely nothing

This was never part of my routine, and it won't be any time soon.

Not because the biology is stupid. It's actually interesting. Because the case is built on injected mice, sold as an oral pill; because the entire efficacy evidence base comes from the people who profit from it; because there is not one human data point on safety or benefit; and because what looks good in the animal data, read honestly, also points at a cardiovascular downside I'm in no position to gamble on. For a guy with a stent, that's not a hard call. It's not even close.

That's the whole point of how I do this. I'm not here to hand you a stack and a discount code. I'm here to tell you what the evidence actually supports, and sometimes the honest answer is I looked, and I walked away.

This is what these are going to be, more and more. Take the thing the longevity world is selling and run it all the way down. Not just the mechanism, which is one step out of ten, but the conflicts, the bioavailability, the dose nobody has actually established, the quality of the evidence itself. The point was never to stop spending. I still spend plenty on my own health. It was to stop guessing. Most of the time the answer isn't don't take this, it's here's what the evidence really is, now you decide. This time, for me, it happened to be no.

I don't eyeball it, either. Every compound runs through a full bioinformatics pipeline: every study pulled and read, every conflict traced to its source, every claim graded against the hallmarks of aging. This post is one thread of that work. The complete breakdown, every study and every score, lives at Calibrated Age.

The Final Signal

• What the claim gets right: the mechanism is real and the animal data are genuine. NNMT inhibition does what they say, in mice, with a needle.
• What it gets wrong: it sells injected-mouse results as an oral human protocol, on zero human data.
• The heart angle: "cardioprotective" is unmeasured, and the compound suppresses a molecule that protects human blood vessels.
• What would change my mind: one randomized human trial, dosed orally, run by someone who doesn't sell it.
• What I changed: nothing.

References

1. Neelakantan H, Vance V, Wetzel MD, et al. "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice." Biochem Pharmacol. 2018;147:141–152. PMID: 29155147 [Finding: In obese mice, the injected compound raised NAD⁺, cut body weight and fat mass, and lowered cholesterol, with no change in food intake.]
2. Dimet-Wiley AL, et al. "Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice." Sci Rep. 2024;14:15554. PMID: 38969654 [Finding: Injected aged mice gained ~40% grip strength, additive to exercise. First author affiliated with the commercializing company.]
3. Neelakantan H, et al. "Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle." Biochem Pharmacol. 2019;163:481–492. PMID: 30753815 [Finding: Injected aged mice showed improved muscle regeneration and ~70% greater peak torque after injury.]
4. Babula JJ, et al. "Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction." Diabetes Obes Metab. 2024;26(11):5272–5282. PMID: 39161060 [Finding: 28-day subcutaneous dosing improved glucose tolerance in obese mice; oral bioavailability in mice was poor. First author affiliated with the commercializing company.]
5. Awosemo O, et al. "Development & validation of LC–MS/MS assay for 5-amino-1-methylquinolinium in rat plasma." J Pharm Biomed Anal. 2021;204:114255. PMID: 34304009 [Finding: Oral bioavailability in rats was ~38%, partial, and the only oral absorption figure that exists in any mammal.]
6. Sampson CM, et al. "Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition... in obese mice." Sci Rep. 2021;11:5637. PMID: 33707534 [Finding: Representative of the efficacy base; the competing-interests statement discloses the company founder and a paid employee as authors.]
7. US Patent Application US20200102274A1. "Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof." Assignee: Board of Regents of the University of Texas System. Priority 2017-03-30. [Finding: 5-amino-1-methylquinolinium iodide is named as exemplar compound "1j"; the originator lab's lead scientists (including the first author of refs 1 and 3) are listed inventors.]
8. Domagała TB, et al. "Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels." Hypertension. 2012;59(4):825–832. PMID: 22353616 [Finding: In humans, oral 1-MNA increased nitric-oxide-dependent (flow-mediated) dilation of the brachial artery, the molecule 5-Amino-1MQ suppresses.]
9. Mateuszuk Ł, et al. "Antiatherosclerotic effects of 1-methylnicotinamide in apolipoprotein E/LDL receptor-deficient mice." J Pharmacol Exp Ther. 2016;356(2):514–524. PMID: 26631491 [Finding: In atherosclerosis-prone mice, 1-MNA reduced plaque, improved NO/prostacyclin-dependent endothelial function, and inhibited platelet activation.]
10. Ferrell M, et al. "A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk." Nat Med. 2024;30(2):424–434. PMID: 38374343 [Finding: In ~4,300 humans, the niacin terminal metabolites 2PY and 4PY tracked with higher 3-year major-adverse-cardiac-event risk, the genuinely two-sided part of the biology, since NNMT inhibition lowers them too.]
11. Li S, et al. "Nicotinamide-N-methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model." Pharmacol Res. 2025. PMID: 40484359 [Finding: In aged "stiff-heart" (HFpEF) mice, NNMT inhibition cut 1-MNA ~77% and improved cardiac function, but the inhibitor was AMO-NAM, a different NNMT blocker, not 5-Amino-1MQ, and the benefit was not via homocysteine.]
12. Campagna R, Mateuszuk Ł, et al. "Nicotinamide N-methyltransferase in endothelium protects against oxidant stress-induced endothelial injury." Biochim Biophys Acta Mol Cell Res. 2021;1868(10):119082. PMID: 34153425 [Finding: Inhibiting NNMT in human endothelial cells reduced their survival under oxidant stress. Used the related compound 5-amino-1-methylquinoline (5MQ), not the 5-amino-1-methylquinolinium sold as 5-Amino-1MQ.]
13. Clarke R, et al. "Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37,485 individuals." Arch Intern Med. 2010;170(18):1622–1631. PMID: 20937919 [Finding: Folic acid lowered homocysteine ~25% but had no significant effect on heart attacks, strokes, or vascular death across 37,485 people. Lowering homocysteine did not lower cardiovascular events.]